Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a
possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not
otherwise specified (HCN NOS).